XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.

XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.
S
S

Sage

Nachrichten

Reuters - vor 2 Wochen

U.S. CH Robinson Worldwide, Dayforce, Entegris

U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Dayforce, Entegris Aug 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CH Robinson Worldwide, Dayforce and Entegris, on Thursday. HIGHLIGHTS * CH Robinson Worldwide Inc CHRW.O : JP Morgan raises to overweight from neutral * Dayforce Inc DAY.N : Piper Sandler raises to overweight from neutral * Entegris Inc ENTG.O : Seaport Research Partners raises to buy from neutral * M
B
C
D
E
M
Q
S
V
A
C
D
E
L
T
P
W
A
B
C
Reuters - vor 2 Wochen

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.70​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-2.68. The mean expectation of twenty analysts for the quarter was for a loss of $1.66 per share.
S
Reuters - vor 2 Wochen

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.66 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Cambridge Massachusetts-based company is expected to report a 258.2% increase in revenue to $8.848 million from $2.47 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S
Reuters - vor 3 Wochen

U.S. Edwards Lifesciences, National Bank Holdings, Sage Therapeutics

U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics July 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Edwards Lifesciences, National Bank Holdings and Sage Therapeutics, on Thursday. HIGHLIGHTS * Edwards Lifesciences Corp EW.N : JP Morgan cuts to neutral from overweight * National Bank Holdings Corp NBHC.N : Piper Sandler cuts to neutral from overweight * Sage Therapeutics Inc S
A
A
C
C
G
S
C
E
H
I
A
A
E
L
Reuters - vor 3 Wochen

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O
Reuters - vor 3 Wochen

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O
Reuters - vor 3 Wochen

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug Updates ** Shares of Sage Therapeutics SAGE.O fall ~ 1 7.5 % to $10.7 9 , its biggest one day loss pct since April ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug f
B
S
Reuters - vor 3 Wochen

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug ** Shares of Sage Therapeutics SAGE.O fall 19% to $10.60 premarket ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug further but may consider it for other potential c
B
S
Reuters - vor 3 Wochen

Biogen and Sage to scrap neurological disorder drug development after trial failure

UPDATE 2-Biogen and Sage to scrap neurological disorder drug development after trial failure Adds share movement in paragraph 2, analyst comment in paragraph 4 July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics SAGE.O do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
B
S
Reuters - vor 3 Wochen

Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of 324 (BIIB124) For The Treatment Of Essential Tremor

BRIEF-Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of SAGE-324 (BIIB124) For The Treatment Of Essential Tremor July 24 (Reuters) - Sage Therapeutics SAGE.O SAGE THERAPEUTICS AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM PHASE 2 KINETIC 2 STUDY OF SAGE-324 (BIIB124) FOR THE TREATMENT OF ESSENTIAL TREMOR SAGE THERAPEU
B
S
Reuters - vor 3 Wochen

Biogen and Sage's neurological disorder drug fails in mid-stage trial

Biogen and Sage's neurological disorder drug fails in mid-stage trial July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics' SAGE.O neurological disorder drug failed in a mid-stage trial, the companies said on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
B
S
Reuters - vor 1 Monat

U.S. Boston Beer Company, Inter Parfums, Netflix

U.S. RESEARCH ROUNDUP-Boston Beer Company, Inter Parfums, Netflix July 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Boston Beer Company, Inter Parfums and Netflix, on Friday. HIGHLIGHTS * Boston Beer Company Inc SAM.N : Piper Sandler cuts PT to $344 from $350 * Inter Parfums Inc IPAR.O : Jefferies raises to buy from hold * Netflix Inc NFLX.O : JP Morgan raises target price to $750 from $650 * Smurfit Westrock SW
C
N
N
P
S
D
E
C
C
E
M
Reuters - vor 1 Monat

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U
Reuters - vor 2 Monaten

U.S. Citigroup, Nike, Tesla

U.S. RESEARCH ROUNDUP-Citigroup, Nike, Tesla June 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Citigroup, Nike and Tesla, on Thursday. HIGHLIGHTS * Bread Financial Holdings Inc BFH.N : Evercore ISI raises to in line from underperform * Citigroup C.N : KBW raises target price to $69 from $66 * Lennar Corp LEN.N : Evercore ISI cuts target price to $237 from $238 * Nike Inc NKE.N : Barclays cuts target price to $1
C
I
M
N
N
S
T
D
F
P
A
A
Reuters - vor 2 Monaten

U.S. STOCKS Affirm, Calavo Growers, Shoals Technologies

BUZZ-U.S. STOCKS ON THE MOVE-Affirm, Calavo Growers, Shoals Technologies Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped on Tuesday as investors turned cautious ahead of a crucial inflation reading and a policy announcement from the Federal Reserve expected this week, although a recovery in Apple's shares helped curtail losses.
A
G
G
J
N
S
R
U
U
S
S
R
Reuters - vor 2 Monaten

U.S. STOCKS Spotify, Affirm, Calavo Growers

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Affirm, Calavo Growers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes declined on Tuesday as caution dampened investor enthusiasm ahead of a crucial inflation reading and a policy announcement from the Federal Reserve expected this week.
A
A
G
J
N
S
R
U
U
S
S
F
R
Reuters - vor 2 Monaten

U.S. STOCKS Sage, General Motors, Viridian

BUZZ-U.S. STOCKS ON THE MOVE-Sage, General Motors, Viridian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set to open lower on Tuesday, with futures tracking all three major indexes in the red as investors were cautious ahead of crucial inflation data and a policy announcement from the Federal Reserve expected this week.
N
S
R
U
S
R
Reuters - vor 2 Monaten

Futures ease on rate-cut jitters ahead of inflation data, Fed meet

US STOCKS-Futures ease on rate-cut jitters ahead of inflation data, Fed meet For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Eli Lilly up as Alzheimer's drug gets US FDA panel backing Crypto stocks fall as bitcoin hits one-week low GM approves $6 billion share buyback plan Futures lower: Dow 0.31%, S&P 0.22%, Nasdaq 0.23% Updated at 8:16 a.m.
A
A
M
N
S
U
U
U
B
Reuters - vor 2 Monaten

Sage climbs as Huntington's drug found to be safe in mid-stage study

BUZZ-Sage climbs as Huntington's drug found to be safe in mid-stage study ** Shares of Sage Therapeutics SAGE.O rise 1.8% to $11.10 premarket ** Drug developer says its drug, dalzanemdor, was found to be safe in patients with a rare, genetic neurological condition called Huntington's disease in a part of a mid-stage study ** SAGE says the study in
S
Reuters - vor 2 Monaten

Futures slip as investors await Fed meeting, CPI numbers

US STOCKS-Futures slip as investors await Fed meeting, CPI numbers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Eli Lilly up as Alzheimer's drug gets US FDA panel backing Crypto stocks fall as bitcoin hits one-week low Futures off: Dow 0.44%, S&P 0.33%, Nasdaq 0.33% Updated at 7:06 a.m.
A
N
S
U
U
U
B

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Risikowarnung: Es bestehen Risiken für Ihr eingesetztes Kapital. Gehebelte Produkte sind nicht für alle Anleger geeignet. Bitte beachten Sie unseren Risikohinweis.